Protalix BioTherapeutics, Inc. Uncategorized Contracts & Agreements
13 Contracts & Agreements
- At the Market Offering Agreement, dated February 27, 2023, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on February 27, 2023)
- Letter Agreement dated August 29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd (Filed With SEC on November 14, 2022)
- Fill/Finish Agreement effective on August 29, 2022 made by and between Chiesi Farmaceutici S.p.A and Protalix Ltd (Filed With SEC on November 14, 2022)
- Letter Amendment dated May 2, 2022 (Filed With SEC on May 2, 2022)
- At the Market Offering Agreement, dated July 2, 2021, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on July 2, 2021)
- Amended and Restated Agreement between Protalix Ltd. and Comercio e Servios Ltda. dated June 17, 2013 (Filed With SEC on May 14, 2021)
- Exhibit A (Filed With SEC on May 8, 2014)
- AGREEMENT (Filed With SEC on May 8, 2014)
- Protalix BioTherapeutics, Inc. (Filed With SEC on March 18, 2011)
- AGREEMENT made and signed on this 14 day of September, 2006 (Filed With SEC on September 20, 2007)
- RESEARCH AND LICENCE AGREEMENT (Filed With SEC on September 20, 2007)
- SCIENTIFICADVISORY BOARD AGREEMENT (Filed With SEC on August 6, 2007)
- EX-10.8 Agreement between Teva and Protalix (Filed With SEC on January 8, 2007)
